| First Author | Hemmati S | Year | 2019 |
| Journal | JCI Insight | Volume | 5 |
| Issue | 13 | PubMed ID | 31120863 |
| Mgi Jnum | J:336308 | Mgi Id | MGI:6753772 |
| Doi | 10.1172/jci.insight.125832 | Citation | Hemmati S, et al. (2019) PI3 kinase alpha and delta promote hematopoietic stem cell activation. JCI Insight 5 |
| abstractText | Many cytokines and chemokines that are important for hematopoiesis activate the PI3K signaling pathway. Because this pathway is frequently mutated and activated in cancer, PI3K inhibitors have been developed for the treatment of several malignancies, and are now being tested in the clinic in combination with chemotherapy. However, the role of PI3K in adult hematopoietic stem cells (HSCs), particularly during hematopoietic stress, is still unclear. We previously showed that the individual PI3K catalytic isoforms P110alpha or P110beta have dispensable roles in HSC function, suggesting redundancy between PI3K isoforms in HSCs. We now demonstrate that simultaneous deletion of P110alpha and P110delta in double knockout (DKO) HSCs uncovers their redundant requirement in HSC cycling after 5-fluorouracil (5-FU) chemotherapy administration. In contrast, DKO HSCs are still able to exit quiescence in response to other stress stimuli, such as LPS. We found that DKO HSCs and progenitors have impaired sensing of inflammatory signals ex vivo, and that levels of IL1-beta and MIG are higher in the bone marrow after LPS than after 5-FU administration. Furthermore, exogenous in vivo administration of IL1-beta can induce cell cycle entry of DKO HSCs. Our findings have important clinical implications for the use of PI3K inhibitors in combination with chemotherapy. |
